Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Topical Cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) on the Ocular Surface Symptom After Photorefractive Keratectomy (PRK) in Feiz Hospital, Isfahan, 2024

NCT06624384 is registered in ClinicalTrials.gov with Mohsen Pourazizi as lead sponsor.

NCT NCT06624384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06624384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Topical Cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) on the Ocular Surface Symptom After Photorefractive Keratectomy (PRK) in Feiz Hospital, Isfahan, 2024
Lead sponsor
Mohsen Pourazizi
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 30, 2024
Completion date
December 30, 2024
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

eye inflammation, eye pain, ocular surface disease, ocular surface symptom